RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating
QuidelOrtho Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Ligand Pharma (LGND) and Bioventus (BVS)
RBC Capital Remains a Buy on QuidelOrtho (QDEL)
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX)
UBS Cuts QuidelOrtho to Sell, Cites Potential Downside to Estimates
QuidelOrtho Analyst Ratings
Craig-Hallum Downgrades QuidelOrtho (QDEL) to a Hold
JPMorgan Cuts Quidel Stock to Underweight, Slashes Target to $37
Citi Cuts Quidel Stock Target to $50, Maintains Neutral Stance
Raymond James Downgrades QuidelOrtho to Outperform, Lowers Price Target to $76
QuidelOrtho Crashes as Analysts Downgrade After Q4 Miss
QuidelOrtho Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: QuidelOrtho (QDEL), Abbott Labs (ABT)
QuidelOrtho (QDEL) Receives a Buy From Craig-Hallum
RBC Capital Sticks to Their Buy Rating for QuidelOrtho (QDEL)
QuidelOrtho Analyst Ratings
QuidelOrtho (QDEL) Gets a Buy From Craig-Hallum